Cingulate Overview

  • Status
  • Public

  • Employees
  • 13

Employees

  • Stock Symbol
  • CING

Stock Symbol

  • Share Price
  • $4.21
  • (As of Friday Closing)

Cingulate General Information

Description

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Contact Information

Website
www.cingulate.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1901 West 47th Place
  • Kansas City, KS 66205
  • United States
+1 (913)
Primary Industry
Pharmaceuticals
Other Industries
Drug Delivery
Biotechnology
Drug Discovery
Stock Exchange
NAS
Vertical(s)
TMT, Life Sciences
Corporate Office
  • 1901 West 47th Place
  • Kansas City, KS 66205
  • United States
+1 (913)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cingulate Stock Performance

As of 13-Dec-2024, Cingulate’s stock price is $4.21. Its current market cap is $13.5M with 3.21M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.21 $4.22 $1.80 - $152.40 $13.5M 3.21M 158K -$43.22

Cingulate Financials Summary

As of 30-Sep-2024, Cingulate has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 15,292 8,786 7,134 30,685
Revenue 0 0 0 0
EBITDA (15,569) (22,176) (17,108) (19,971)
Net Income (16,348) (23,535) (17,676) (20,710)
Total Assets 13,580 3,491 11,405 22,886
Total Debt 234 3,510 5,866 881
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cingulate Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cingulate‘s full profile, request access.

Request a free trial

Cingulate Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug deliv
Pharmaceuticals
Kansas City, KS
13 As of 2023

Portland, OR
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cingulate Competitors (14)

One of Cingulate’s 14 competitors is PDX Pharmaceuticals, a Venture Capital-Backed company based in Portland, OR.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
PDX Pharmaceuticals Venture Capital-Backed Portland, OR
Blueprint Medicines Formerly VC-backed Cambridge, MA
BBS Nanotechnology Venture Capital-Backed Debrecen, Hungary
Cornerstone Pharmaceuticals Venture Capital-Backed Cranbury, NJ
Heron Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 14 competitors. Get the full list »

Cingulate Patents

  • 24

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Cingulate Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023222759-A1 Trimodal, precision-timed release tablet Pending 16-Feb-2022
JP-7449577-B2 Information processing device, information processing method, and program Active 17-May-2021
CA-3219762-A1 Trimodal, precision-timed pulsatile release tablet Pending 11-May-2021
AU-2022272918-A1 Trimodal, precision-timed pulsatile release tablet Pending 11-May-2021
JP-2024518515-A Trimodal precision timing pulsed tablet release Pending 11-May-2021 A61K9/209
To view Cingulate’s complete patent history, request access »

Cingulate Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cingulate Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cingulate‘s full profile, request access.

Request a free trial

Cingulate FAQs

  • Where is Cingulate headquartered?

    Cingulate is headquartered in Kansas City, KS.

  • What is the size of Cingulate?

    Cingulate has 13 total employees.

  • What industry is Cingulate in?

    Cingulate’s primary industry is Pharmaceuticals.

  • Is Cingulate a private or public company?

    Cingulate is a Public company.

  • What is Cingulate’s stock symbol?

    The ticker symbol for Cingulate is CING.

  • What is the current stock price of Cingulate?

    As of 13-Dec-2024 the stock price of Cingulate is $4.21.

  • What is the current market cap of Cingulate?

    The current market capitalization of Cingulate is $13.5M.

  • Who are Cingulate’s competitors?

    PDX Pharmaceuticals, Blueprint Medicines, BBS Nanotechnology, Cornerstone Pharmaceuticals, and Heron Therapeutics are some of the 14 competitors of Cingulate.

  • What is Cingulate’s annual earnings per share (EPS)?

    Cingulate’s EPS for 12 months was -$43.22.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »